Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “hold” rating reaffirmed by stock analysts at Stifel Nicolaus in a research report issued to clients and investors on Wednesday. They presently have a $83.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $56.00. Stifel Nicolaus’ price objective indicates a potential downside of 27.05% from the company’s previous close.

Other equities analysts have also recently issued research reports about the company. Morgan Stanley reiterated an “equal weight” rating on shares of Alnylam Pharmaceuticals in a report on Monday, July 10th. BidaskClub cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 16th. Needham & Company LLC increased their target price on Alnylam Pharmaceuticals from $85.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday. J P Morgan Chase & Co reiterated a “hold” rating on shares of Alnylam Pharmaceuticals in a report on Monday, June 26th. Finally, Chardan Capital reiterated a “buy” rating and set a $131.00 target price (up previously from $110.00) on shares of Alnylam Pharmaceuticals in a report on Monday, July 10th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the company. Alnylam Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $91.59.

Alnylam Pharmaceuticals (NASDAQ ALNY) opened at 112.92 on Wednesday. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $117.44. The stock’s market cap is $10.36 billion. The firm has a 50-day moving average price of $81.14 and a 200-day moving average price of $69.12. Alnylam Pharmaceuticals also was the target of unusually large options trading on Wednesday. Stock investors bought 30,530 call options on the stock. This is an increase of approximately 937% compared to the typical daily volume of 2,944 call options.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.12). The business had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The business’s quarterly revenue was up 82.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.05) EPS. On average, equities research analysts predict that Alnylam Pharmaceuticals will post ($5.20) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/21/alnylam-pharmaceuticals-inc-alny-stock-rating-reaffirmed-by-stifel-nicolaus.html.

Large investors have recently modified their holdings of the stock. QS Investors LLC lifted its stake in Alnylam Pharmaceuticals by 59.7% in the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 900 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Alnylam Pharmaceuticals by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 167 shares during the last quarter. CIBC Asset Management Inc acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $221,000. Neuberger Berman Group LLC acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $229,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Alnylam Pharmaceuticals in the 1st quarter valued at about $148,000. Institutional investors and hedge funds own 94.25% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.